Company Description
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody.
Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.
The company was incorporated in 2019 and is based in Waltham, Massachusetts.
| Country | United States |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 114 |
| CEO | Leon Oliver Moulder Jr., M.B.A. |
Contact Details
Address: North Building Waltham, Massachusetts United States | |
| Website | https://zenasbio.com |
Stock Details
| Ticker Symbol | ZBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001953926 |
| CUSIP Number | n/a |
| ISIN Number | US98937L1052 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leon Oliver Moulder Jr., M.B.A. | Chief Executive Officer & Chairman of the Board |
| Jeffrey Held | Chief Legal Officer |
| Jennifer A. Fox | Chief Business Officer & Chief Financial Officer |
| Joseph L. Farmer | Chief Operating Officer & President |
| Caroline Chevalier | Chief Human Resources Officer |
| Dr. Tanya Z. Fischer M.D., Ph.D. | Head of Research & Development and Chief Medical Officer. |
| Orlando Oliveira | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 04, 2024 | 4 | Filing |
| Dec 02, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 4 | Filing |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |